Lancet neurology
-
Randomized Controlled Trial Multicenter Study
Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial.
Depletion of B lymphocytes is associated with suppression of inflammatory activity in multiple sclerosis. We aimed to assess the safety and efficacy of atacicept, a recombinant fusion protein that suppresses B-cell function and antibody production. ⋯ Merck Serono (Merck KGaA) and EMD Serono (Merck KGaA).